The continuing saga of snake venom disintegrins

Toxicon

Volumn 62, Issue , 2013, Pages 40-49

  Calvete, Juan J ^a  

^a INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

Author keywords

Cell adhesion antagonist; Disintegrin; Platelet receptor antagonist; Snake venom toxin; Toxin evolution

Indexed keywords

BETA1 INTEGRIN; BILITOXIN 1; BITISTATIN; CONTORTROSTATIN; CYSTEINE; DISINTEGRIN; DISULFIDE; ECHISTATIN; EPTIFIBATIDE; INTEGRILLIN; OBTUSTATIN; TIROFIBAN; TRIGRAMIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANTIANGIOGENIC ACTIVITY; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CHEMICAL BOND; CRYSTAL STRUCTURE; HEART MUSCLE ISCHEMIA; HUMAN; MOLECULAR INTERACTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHARMACEUTICAL CARE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; X RAY ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CONSERVED SEQUENCE; DISINTEGRINS; EVOLUTION, MOLECULAR; HUMANS; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; SNAKE VENOMS; STRUCTURE-ACTIVITY RELATIONSHIP;

CROTALUS; SERPENTES; VIPERIDAE; VIPERINAE;

EID: 84872496139     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2012.09.005     Document Type: Review

References (62)

1. Bauer M., Sun Y., Degenhardt C., Kozikowski B. Assignment of all four disulfide bridges in echistatin. J. Protein Chem. 1993, 12:759-764.
2. Bazaa A., Juárez P., Marrakchi N., Lasfer Z.B., El Ayeb M., Harrison R.A., Calvete J.J., Sanz L. Loss of introns along the evolutionary diversification pathway of snake venom disintegrins evidenced by sequence analysis of genomic DNA from Macrovipera lebetina transmediterranea and Echis ocellatus. J. Mol. Evol. 2007, 64:261-271.
3. Bilgrami S., Tomar S., Yadav S., Kaur P., Kumar J., Jabeen T., Sharma S., Singh T.P. Crystal structure of schistatin, a disintegrin homodimer from saw-scaled viper (Echis carinatus) at 2.5 ≈ resolution. J. Mol. Biol. 2004, 341:829-837.
4. Bilgrami S., Yadav S., Sharma S., Perbandt M., Betzel C., Singh T.P. Crystal structure of the disintegrin heterodimer from saw-scaled viper (Echis carinatus) at 1.9 ≈ resolution. Biochemistry 2005, 44:11058-11066.
5. Bougie D.W., Wilker P.R., Wuitschick E.D., Curtis B.R., Malik M., Levine S., Lind R.N., Pereira J., Aster R.H. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002, 100:2071-2076.
6. Bougie D.W., Nayak D., Boylan B., Newman P.J., Aster R.H. Drug-dependent clearance of human platelets in the NOD/scid mouse by antibodies from patients with drug-induced immune thrombocytopenia. Blood 2010, 116:3033-3038.
7. Calvete J.J., Schäfer W., Soszka T., Lu W.Q., Cook J.J., Jameson B.A., Niewiarowski S. Identification of the disulfide bond pattern in albolabrin, an RGD-containing peptide from the venom of Trimeresurus albolabris: significance for the expression of platelet aggregation inhibitory activity. Biochemistry 1991, 30:5225-5229.
8. Calvete J.J., McLane M.A., Stewart G.J., Niewiarowski S. Characterization of the cross-linking site of disintegrins albolabrin, bitistatin, echistatin, and eristostatin on isolated human platelet integrin GPIIb/IIIa. Biochem. Biophys. Res. Commun. 1994, 202:135-140.
9. Calvete J.J., Jürgens M., Marcinkiewicz C., Romero A., Schrader M., Niewiarowski S. Disulfide bond pattern and molecular modelling of the dimeric disintegrin EMF-10, a potent and selective integrin α5β1 antagonist from Eristocophis macmahoni venom. Biochem. J. 2000, 345:573-581.
10. Calvete J.J., Moreno-Murciano M.P., Theakston R.D.G., Kisiel D.G., Marcinkiewicz C. Snake venom disintegrins: novel dimeric disintegrins and structural diversification by disulfide bond engineering. Biochem. J. 2003, 372:725-734.
11. Calvete J.J., Marcinkiewicz C., Monleón D., Esteve V., Celda B., Juárez P., Sanz L. Snake venom disintegrins: evolution of structure and function. Toxicon 2005, 45:1063-1074.
12. Calvete J.J., Marcinkiewicz C., Sanz L. KTS- and RTS-disintegrins: anti angiogenic viper venom peptides specifically targeting the α1β1 integrin. Curr. Pharm. Des. 2007, 13:2853-2859.
13. Calvete J.J., Juárez P., Sanz L. Snake venomics and disintegrins. Portrait and evolution of a family of snake venom integrin antagonists. Handbook of Venoms and Toxins of Reptiles 2009, 337-357. CRC Press, Taylor & Francis, Boca Ratón, (Chapter 17). S.P. Mackessy (Ed.).
14. Calvete J.J. Brief history and molecular determinants of snake venom disintegrin evolution. Toxins and Hemostasis: From Bench to Bedside 2010, 285-300. Springer, Amsterdam, (Chapter 18). R.M. Kini, F. Markland, M.A. McLane, T. Morita (Eds.).
15. Carbajo R.J., Sanz L., Mosulén S., Pérez A., Marcinkiewicz C., Pineda-Lucena A., Calvete J.J. NMR structure and dynamics of recombinant wild type and mutated jerdostatin, a selective inhibitor of integrin α1β1. Proteins 2011, 79:2530-2542.
16. Castoe T.A., Daza J.M., Smith E.N., Sasa M., Kuch U., Campbell J.A., Chippindale P.T., Parkinson C.L. Comparative phylogeography of pitvipers suggests a consensus of ancient Middle American highland biogeography. J. Biogeogr. 2009, 36:88-103.
17. Cook J.J., Huang T.-F., Rucinski B., Strzyzewski M., Tuma R.F., Williams J.A., Niewiarowski S. Inhibition of platelet hemostatic plug formation by trigramin, a novel RGD-peptide. Am. J. Physiol. 1989, 256:H1038-H1043.
18. Fry B.G., Wüster W. Assembling an arsenal: origin and evolution of the snake venom proteome inferred from phylogenetic analysis of toxin sequences. Mol. Biol. Evol. 2004, 21:870-883.
19. Fry B.G. From genome to " venome" : molecular origin and evolution of the snake venom proteome inferred from phylogenetic analysis of toxin sequences and related body proteins. Genome Res. 2005, 15:403-420.
20. Fry B.G., Vidal N., Norman J.A., Vonk F.J., Scheib H., Ramjan S.F., Kuruppu S., Fung K., Hedges S.B., Richardson M.K., Hodgson W.C., Ignjatovic V., Summerhayes R., Kochva E. Early evolution of the venom system in lizards and snakes. Nature 2006, 439:584-588.
21. Gould R.J., Polokoff M.A., Friedman P.A., Huang T.-F., Holt J.C., Cook J.J., Niewiarowski S. Proc. Soc. Exp. Biol. Med. 1990, 195:168-171.
22. Harvey A.L., Bradley K.N., Cochran S.A., Rowan E.G., Pratt J.A., Quillfeldt J.A., Jerusalinsky D.A. What can toxins tell us for drug discovery?. Toxicon 1998, 36:1635-1640.
23. Hong S.Y., Sohn Y.D., Chung K.H., Kim D.S. Structural and functional significance of disulfide bonds in saxatilin, a 7.7 kDa disintegrin. Arch. Biochem. Biophys. 2002, 293:530-536.
24. Huang T.F., Holt J.C., Lukasiewicz H., Niewiarowski S. Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex. J. Biol. Chem. 1987, 262:16157-16163.
25. Huang T.-F., Holt J.C., Kirby E.P., Niewiarowski S. Trigramin: primary structure and its inhibition of Von Willebrand factor binding to glycoprotein IIb/IIIa complex on human platelets. Biochemistry 1989, 28:661-666.
26. Huang T.-F. The discovery of disintegrins. Toxins and Hemostasis: From Bench to Bedside 2010, 269-284. Springer, Amsterdam, (Chapter 17). R.M. Kini, F. Markland, M.A. McLane, T. Morita (Eds.).
27. Juárez P., Comas I., González-Candelas F., Calvete J.J. Evolution of snake venom disintegrins by positive Darwinian selection. Mol. Biol. Evol. 2008, 25:2391-2407.
28. Kini R., Evans H.J. Structural domains in venom proteins: evidence that metalloproteinases and nonenzymatic platelet aggregation inhibitors (disintegrins) from snake venoms are derived by proteolysis from a common precursor. Toxicon 1992, 30:265-293.
29. 99mTc-bitistatin, a platelet-binding polypeptide from viper venom. J. Nucl. Med. 2000, 41:1056-1064.
30. Knight L.C., Romano J.E. Functional expression of bitistatin, a disintegrin with potential use in molecular imaging of thromboembolic disease. Protein Expr. Purif. 2005, 39:307-319.
31. 99mTc]rBitistatin in animal species and humans. Nucl. Med. Biol. 2007, 34:855-863.
32. Koh D.C.I., Armugam A., Jeyaseelan K. Snake venom components and their applications in biomedicine. Cell. Mol. Life Sci. 2006, 63:3030-3041.
33. Koh C.Y., Kini R.M. From snake venom toxins to therapeutics - cardiovascular examples. Toxicon 2012, 59:497-506.
34. Lenk P., Kalyabina S., Wink M., Joger U. Evolutionary relationships among the true vipers (Reptilia: Viperidae) inferred from mitochondrial DNA sequences. Mol. Phylogenet. Evol. 2001, 19:94-104.
35. Marcinkiewicz C., Calvete J.J., Marcinkiewicz M.M., Raida M., Vijay-Kumar S., Huang Z., Lobb R.R., Niewiarowski S. EC3, a novel heterodimeric disintegrin from Echis carinatus venom, inhibits α4 and α5 integrins in an RGD-independent manner. J. Biol. Chem. 1999, 274:12468-12473.
36. Marcinkiewicz C., Calvete J.J., Vijay-Kumar S., Marcinkiewicz M.M., Raida M., Schick P., Lobb R.R., Niewiarowski S. Structural and functional characterization of EMF10, a heterodimeric disintegrin from Eristocophis macmahoni venom that selectively inhibits α5β1 integrin. Biochemistry 1999, 38:13302-13309.
37. Marcinkiewicz C., Wainreb P.H., Calvete J.J., Kisiel D.G., Mousa S.A., Tuszynski G.P., Lobb R.R. Obtustatin, a potent inhibitor of α1β1 integrin in vitro and angiogenesis in vivo. Cancer Res. 2003, 63:2020-2023.
38. Marcinkiewicz C. Functional characteristic of snake venom disintegrins: potential therapeutic implication. Curr. Pharm. Des. 2005, 11:815-827.
39. Marcinkiewicz C. Pharmacological impact of snake venom compounds. Curr. Pharm. Des. 2007, 13:2851-2922.
40. McLane M.A., Kowalska M.A., Silver L., Shattil S.J., Niewiarowski S. Interaction of disintegrins with the αIIbβ3 receptor on resting and activated human platelets. Biochem. J. 1994, 301:429-436.
41. McLane M.A., Joerger T., Mahmoud A. Disintegrins in health and disease. Front. Biosci. 2008, 13:6617-6637.
42. Monleón D., Moreno-Murciano M.P., Kovacs H., Marcinkiewicz C., Calvete J.J., Celda B. Concerted motions of the integrin-binding loop and the C-terminal tail of the non-RGD disintegrin obtustatin. J. Biol. Chem. 2003, 278:45570-45576.
43. Monleón D., Esteve V., Kovacs H., Calvete J.J., Celda B. Conformation and concerted dynamics of the integrin-binding site and the C-terminal region of echistatin revealed by homonuclear NMR. Biochem. J. 2005, 387:57-66.
44. Moreno-Murciano M.P., Monleón D., Marcinkiewicz C., Calvete J.J., Celda B. NMR solution structure of the non-RGD disintegrin obtustatin. J. Mol. Biol. 2003, 329:135-145.
45. Moura-da-Silva A.M., Theakston R.D., Crampton J.M. Evolution of disintegrin cysteine-rich and mammalian matrix-degrading metalloproteinases: gene duplication and divergence of a common ancestor rather than convergent evolution. J. Mol. Evol. 1996, 43:263-269.
46. Nikai T., Taniguchi K., Komori Y., Masuda K., Fox J.W., Sugihara S. Primary structure and functional characterization of bilitoxin-1, a novel dimeric P-II snake venom metalloproteinase from Agkistrodon bilineatus venom. Arch. Biochem. Biophys. 2000, 378:6-15.
47. Ogawa T., Chijiwa T., Oda-Ueda N., Ohno M. Molecular diversity and accelerated evolution of C-type lectin-like proteins from snake venom. Toxicon 2005, 45:1-14.
48. Okuda D., Koike H., Morita T. A new gene structure of the disintegrin family: a subunit of dimeric disintegrin has a short coding region. Biochemistry 2002, 41:14248-14254.
49. Sanz L., Bazaa A., Marrakchi N., Pérez A., Chenik M., Bel Lasfer Z., El Ayeb M., Calvete J.J. Molecular cloning of disintegrins from Cerastes vipera and Macrovipera lebetina transmediterranea venom gland cDNA libraries. Insight into the evolution of the snake venom's integrin inhibition system. Biochem. J. 2006, 395:385-392.
50. Saudek V., Atkinson R.A., Pelton J.T. Three-dimensional structure of echistatin, the smallest active RGD protein. Biochemistry 1991, 30:7369-7372.
51. Scarborough R.M., Rose J.W., Hsu M.A., Phillips D.R., Fried V.A., Campbell A.M., Nannizzi L., Charo I.F. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J. Biol. Chem. 1991, 266:9359-9362.
52. Scarborough R.M., Naughton M.A., Teng W., Rose J.W., Phillips D.R., Nannizzi L., Arfsten A., Campbell A.M., Charo I.F. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J. Biol. Chem. 1993, 268:1066-1073.
53. Scarborough R.M. Development of eptifibatide. Am. Heart J. 1999, 138:1093-1104.
54. Shin J., Hong S.Y., Chung K., Kang I., Jang Y., Kim D.S., Lee W. Solution structure of a novel disintegrin, salmosin, from Agkistrondon halys venom. Biochemistry 2003, 42:14408-14415.
55. 1H NMR spectroscopy and simulated annealing calculations. Int. J. Pept. Protein Res. 1996, 48:220-228.
56. Swenson S., Ramu S., Markland F.S. Anti-angiogenesis and RGD-containing snake venom disintegrins. Curr. Pharm. Des. 2007, 13:2860-2871.
57. Tcheng J.E., Harrington R.A., Kottke M.K., Kleinman N.S., Ellis S.G., Kereiakes D.J., Mick M.J., Navetta F.I., Smith J.E., Worley S.J., Miller J.A., Joseph D.M., Sigmon K.N., Kitt M.M., du Mée C.P., Califf R.M., Topol E.J. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation 1995, 91:2151-2157.
58. Vidal N. Colubroid systematics: evidence for an early appearance of the venom apparatus followed by extensive evolutionary tinkering. J. Toxicol. Toxin. Rev. 2002, 21:21-41.
59. 1 integrins. J. Biol. Chem. 1999, 274:37809-37814.
60. Wright P.S., Saudek V., Owen T.J., Harbeson S.L., Bitonti A.J. An echistatin C-terminal peptide activates GPIIbIIIa binding to fibrinogen, fibronectin, vitronectin and collagen type I and type IV. Biochem. J. 1993, 293:263-267.
61. Xiong J.-P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L., Arnaout M.A. The crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science 2002, 296:151-155.
62. Zhou Q., Sherwin R.P., Parrish C., Richters V., Groshen S.G., Tsao-Wei D., Markland F.S. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression. Breast Cancer Res. Treat. 2000, 61:249-260.